

# Michael J. Sorich

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8138505/michael-j-sorich-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

159  
papers

3,855  
citations

31  
h-index

58  
g-index

171  
ext. papers

4,680  
ext. citations

4.5  
avg, IF

5.69  
L-index

#	Paper	IF	Citations
159	Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	5
158	A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma.. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2022</b> , 89, 479	3.5	
157	Efficacy of atezolizumab in patients with advanced non-small cell lung cancer receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomised control trials.: Proton pump inhibitors, antibiotics, and immunotherapies.. <i>Journal of Thoracic Oncology</i> , <b>2022</b> , 17, 100-110	8.9	3
156	The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy.. <i>Translational Lung Cancer Research</i> , <b>2022</b> , 11, 432-439	4.4	2
155	Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. <i>Bladder Cancer</i> , <b>2022</b> , 8, 81-88	1	2
154	Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials: Smoking and immunotherapy efficacy in lung cancer. <i>European Journal of Cancer</i> , <b>2021</b> ,	7.5	0
153	Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy.. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> ,	3.3	1
152	Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	8
151	The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 30	7.8	6
150	Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
149	Regarding the Article by Rugo et al. <i>Oncologist</i> , <b>2021</b> , 26, e1285	5.7	1
148	Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	3
147	Exploring the Use of Serum-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting Polypeptides. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 248-258	6.1	12
146	Relationship Between Apparent Systemic Clearance of Vemurafenib and Toxicity in Patients With Melanoma. <i>Journal of Clinical Pharmacology</i> , <b>2021</b> , 61, 1243-1248	2.9	1
145	Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib. <i>Oncologist</i> , <b>2021</b> , 26, 562-568	5.7	2
144	Use of Multiprognostic Index Domain Scores, Clinical Data, and Machine Learning to Improve 12-Month Mortality Risk Prediction in Older Hospitalized Patients: Prospective Cohort Study. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e26139	7.6	0
143	Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events. <i>Journal of Oncology</i> , <b>2021</b> , 2021, 2414897	4.5	

142	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , <b>2021</b> , 45, 100637	2.3	6
141	Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer. <i>Medical Decision Making</i> , <b>2021</b> , 41, 179-193	2.5	5
140	Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a multicohort analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211009020	3.8	1
139	Importance of between and within Subject Variability in Extracellular Vesicle Abundance and Cargo when Performing Biomarker Analyses. <i>Cells</i> , <b>2021</b> , 10,	7.9	9
138	Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
137	Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176". <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
136	Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 803-821	5.5	3
135	Role of Extracellular Vesicle-Derived Biomarkers in Drug Metabolism and Disposition. <i>Drug Metabolism and Disposition</i> , <b>2021</b> , 49, 961-971	4	5
134	RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	0
133	Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib. <i>Breast</i> , <b>2021</b> , 58, 57-62	3.6	2
132	Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin. <i>AAPS Journal</i> , <b>2021</b> , 23, 104	3.7	4
131	Commentary: Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 732622	5.6	
130	Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure. <i>AAPS Journal</i> , <b>2021</b> , 23, 15	3.7	3
129	Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients. <i>International Journal of Clinical Oncology</i> , <b>2020</b> , 25, 1672-1677	4.7	5
128	Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy-Reply. <i>JAMA Oncology</i> , <b>2020</b> , 6, 941-942	13.4	0
127	Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3085-3089	7.5	8
126	Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab <b>2020</b> , 8,		6
125	Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	18

124	Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials. <i>BMC Cancer</i> , <b>2020</b> , 20, 157	4.8	3
123	A literature review of treatment-specific clinical prediction models in patients with breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 148, 102908	7	7
122	Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting. <i>Value in Health</i> , <b>2020</b> , 23, 388-396	3.3	4
121	Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3280-3286	12.9	18
120	Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1191-1199	7.3	8
119	The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2693-2697	4.9	5
118	Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , <b>2020</b> , 6, 512-518	13.4	85
117	Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, e220-e228	3	5
116	Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma. <i>Melanoma Research</i> , <b>2020</b> , 30, 268-271	3.3	1
115	Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 615-620	3.5	6
114	Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo@ Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. <i>Eur Urol</i> 2020;78:540-3. <i>European Urology</i> , <b>2020</b> , 78, e227	10.2	
113	Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. <i>European Urology</i> , <b>2020</b> , 78, 540-543	10.2	33
112	The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1130	5.3	3
111	Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. <i>Scientific Reports</i> , <b>2020</b> , 10, 18634	4.9	3
110	Nuances to precision dosing strategies of targeted cancer medicines. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00625	3.1	3
109	Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5487-5493	12.9	23
108	Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920944359	5.4	5
107	Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine. <i>Journal of Cancer</i> , <b>2020</b> , 11, 3327-3333	4.5	2

106	Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, e208	8.9	1
105	Author@ Reply. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, e210	8.9	
104	Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 789	5.3	4
103	Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data. <i>Cancer Biology and Medicine</i> , <b>2019</b> , 16, 341-349	5.2	2
102	Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1440-1446	8.9	53
101	Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 59, 872-879	2.9	13
100	Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction. <i>AAPS Journal</i> , <b>2019</b> , 21, 78	3.7	20
99	Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 1211-1218	2.8	2
98	Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine. <i>Breast</i> , <b>2019</b> , 46, 90-94	3.6	5
97	Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 473-477	4.4	3
96	Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1120	5.6	4
95	Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. <i>Targeted Oncology</i> , <b>2019</b> , 14, 743-748	5	4
94	Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3531-3531	2.2	1
93	Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data. <i>Pigment Cell and Melanoma Research</i> , <b>2019</b> , 32, 576-583	4.5	8
92	Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. <i>Seminars in Oncology</i> , <b>2019</b> , 46, 380-384	5.5	14
91	Validation and Adaptation of the Multidimensional Prognostic Index in an Older Australian Cohort. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	4
90	Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 216-226	3.8	46
89	Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758834018753090	5.4	3

88	Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 104, 1219-1228	6.1	21
87	Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 913-920	2.8	17
86	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , <b>2018</b> , 57, 1438-1444	3.2	48
85	Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 501-509	3.8	12
84	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 462-476	3.8	40
83	Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability. <i>BMC Medicine</i> , <b>2018</b> , 16, 165	11.4	15
82	Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. <i>Cancers</i> , <b>2018</b> , 10,	6.6	2
81	The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?. <i>Pharmaceutical Research</i> , <b>2017</b> , 34, 1544-1550	4.5	13
80	Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio: could a drug-induced toxicity be regulating exposure to the offending agent?. <i>European Journal of Clinical Pharmacology</i> , <b>2017</b> , 73, 1051-1052	2.8	
79	Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme. <i>Australian Health Review</i> , <b>2017</b> , 41, 1-6	1.8	5
78	Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 576-583	2.3	6
77	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 913-920	8.7	111
76	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 31-49	5.5	37
75	Preface to Precision Dosing of Targeted Anti-Cancer Drugs. <i>Translational Cancer Research</i> , <b>2017</b> , 6, S1498-S1499		
74	Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1643-9	4.1	8
73	Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1725-1732	2.6	10
72	Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2293-9	7.5	17
71	Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 1313-7	8.7	29



70	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. <i>European Journal of Cancer</i> , <b>2016</b> , 55, 122-30	7.5	26
69	Targeted pharmacotherapy after somatic cancer mutation screening. <i>F1000Research</i> , <b>2016</b> , 5, 1551	3.6	7
68	Prolonged induction of warfarin metabolism and a paradoxical INR response in a mitral valve replacement patient receiving rifampicin for infective endocarditis. <i>Biomedical Research and Clinical Practice</i> , <b>2016</b> , 1, 62-65	1.3	3
67	Targeted pharmacotherapy after somatic cancer mutation screening. <i>F1000Research</i> , <b>2016</b> , 5, 1551	3.6	4
66	Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. <i>Medical Journal of Australia</i> , <b>2016</b> , 204, 64-8	4	11
65	Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and Assessment of Metabolic Drug-Drug Interactions Involving Modafinil. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 517	5.6	8
64	Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?. <i>International Journal of Clinical Practice</i> , <b>2016</b> , 70, 340-50	2.9	2
63	The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies—a systematic review. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 411-23	2.8	11
62	Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 48	5.7	18
61	In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 1806-14	4	31
60	Reply: Comment on Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1635	8.7	6
59	Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human disease. <i>Clinica Chimica Acta</i> , <b>2015</b> , 447, 59-65	6.2	10
58	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. <i>Annals of Oncology</i> , <b>2015</b> , 26, 13-21	10.3	351
57	Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. <i>Therapeutic Advances in Drug Safety</i> , <b>2015</b> , 6, 186-8	3.5	7
56	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1888-94	8.7	223
55	BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14605-e14605	2.2	
54	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 424-31	3.5	30
53	Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 1-5	3.5	9

52	Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 235-40	3.5	9
51	CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. <i>Circulation: Cardiovascular Genetics</i> , <b>2014</b> , 7, 895-902		77
50	Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders. <i>Biomarkers in Medicine</i> , <b>2014</b> , 8, 331-44	2.3	45
49	Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. <i>Therapeutic Advances in Drug Safety</i> , <b>2014</b> , 5, 62-6	3.5	8
48	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 350-5	3.5	23
47	Can cancer registries show whether treatment is contributing to survival increases for melanoma of the skin at a population level?. <i>Journal of Evaluation in Clinical Practice</i> , <b>2014</b> , 20, 74-80	2.5	2
46	Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer. <i>Journal of Clinical Epidemiology</i> , <b>2014</b> , 67, 966-72	5.7	7
45	Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. <i>Pharmacoeconomics</i> , <b>2013</b> , 31, 377-91	4.4	13
44	Increased abundance of <i>Sutterella</i> spp. and <i>Ruminococcus torques</i> in feces of children with autism spectrum disorder. <i>Molecular Autism</i> , <b>2013</b> , 4, 42	6.5	236
43	Predicted metabolic drug clearance with increasing adult age. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 1019-28	3.8	38
42	Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 376-82	6.1	19
41	Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 2013-21	2.6	23
40	Consumer-pharmacist interactions around complementary medicines: agreement between pharmacist and consumer expectations, satisfaction and pharmacist influence. <i>International Journal of Pharmacy Practice</i> , <b>2013</b> , 21, 378-85	1.7	21
39	Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 1025-35	5.5	32
38	Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups. <i>PLoS ONE</i> , <b>2013</b> , 8, e72256	3.7	4
37	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R163	5.7	37
36	Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 199-200	7	17
35	Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 2096-102	4	233



34	Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 889-99	2.6	45
33	Pharmacogenomics and Personalised Medicine: Consumer Perspectives, Lessons Learned in Australia and Beyond. <i>Current Pharmacogenomics and Personalized Medicine</i> , <b>2012</b> , 10, 170-177	0.4	1
32	Personalized medicine: potential, barriers and contemporary issues. <i>Current Drug Metabolism</i> , <b>2012</b> , 13, 1000-6	3.5	15
31	Reforming Pharmaceutical Education to Enhance the Global Uptake of Pharmacogenomics and Personalized Medicine. <i>Current Pharmacogenomics and Personalized Medicine</i> , <b>2012</b> , 10, 231-238	0.4	3
30	A review of candidate urinary biomarkers for autism spectrum disorder. <i>Biomarkers</i> , <b>2011</b> , 16, 537-52	2.6	31
29	Unanswered Health-Related Questions in Community Pharmacy: Frequency, Nature and Consequences. <i>Journal of Pharmacy Practice and Research</i> , <b>2011</b> , 41, 271-274	0.7	1
28	The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 27-9	6.1	7
27	Low relative abundances of the mucolytic bacterium <i>Akkermansia muciniphila</i> and <i>Bifidobacterium</i> spp. in feces of children with autism. <i>Applied and Environmental Microbiology</i> , <b>2011</b> , 77, 6718-21	4.8	253
26	Pharmacists' Role in targeted cancer therapy in Australia and implications for pharmacy education. <i>American Journal of Pharmaceutical Education</i> , <b>2010</b> , 74, 168	2.5	4
25	Is there a role for routinely screening children with autism spectrum disorder for creatine deficiency syndrome?. <i>Autism Research</i> , <b>2010</b> , 3, 268-72	5.1	10
24	Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 1678-84	15.4	76
23	The Effect of Molecular Fields, Lattice Spacing and Analysis Options on CoMFA Predictive Ability. <i>QSAR and Combinatorial Science</i> , <b>2009</b> , 28, 637-644		4
22	Comparison data sets for benchmarking QSAR methodologies in lead optimization. <i>Journal of Chemical Information and Modeling</i> , <b>2009</b> , 49, 1810-20	6.1	16
21	Is urinary indolyl-3-acryloylglycine a biomarker for autism with gastrointestinal symptoms?. <i>Biomarkers</i> , <b>2009</b> , 14, 596-603	2.6	17
20	Partial charge calculation method affects CoMFA QSAR prediction accuracy. <i>Journal of Chemical Information and Modeling</i> , <b>2009</b> , 49, 704-9	6.1	53
19	Cytochrome P450 Part 3: Impact of Drug-Drug Interactions. <i>Journal of Pharmacy Practice and Research</i> , <b>2009</b> , 39, 55-58	0.7	4
18	In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. <i>PLoS Medicine</i> , <b>2008</b> , 5, e83	11.6	60
17	Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates. <i>Current Drug Metabolism</i> , <b>2008</b> , 9, 60-9	3.5	19

16	Cytochrome P450 Part 2: Genetics of Inter-Individual Variability. <i>Journal of Pharmacy Practice and Research</i> , <b>2008</b> , 38, 226-229	0.7	2
15	Cytochrome P450 Part 1: Multiplicity and Function. <i>Journal of Pharmacy Practice and Research</i> , <b>2008</b> , 38, 55-57	0.7	17
14	Effect of steric molecular field settings on CoMFA predictivity. <i>Journal of Molecular Modeling</i> , <b>2008</b> , 14, 59-67	2	8
13	A critical analysis of barriers to the clinical implementation of pharmacogenomics. <i>Therapeutics and Clinical Risk Management</i> , <b>2007</b> , 3, 751-9	2.9	45
12	Systematic statistical comparison of comparative molecular similarity indices analysis molecular fields for computer-aided lead optimization. <i>Journal of Chemical Information and Modeling</i> , <b>2006</b> , 46, 2015-21	6.1	7
11	Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. <i>Journal of Chemical Information and Modeling</i> , <b>2006</b> , 46, 2661-73	6.1	31
10	The importance of local chemical structure for chemical metabolism by human uridine 5 $\alpha$ -diphosphate-glucuronosyltransferase. <i>Journal of Chemical Information and Modeling</i> , <b>2006</b> , 46, 2692-7	6.1	31
9	Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. <i>Molecular Pharmacology</i> , <b>2004</b> , 65, 301-8	4.3	59
8	Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. <i>Journal of Molecular Graphics and Modelling</i> , <b>2004</b> , 22, 507-17	2.8	47
7	Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2004</b> , 44, 1-25	17.9	189
6	Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 5311-7	8.3	42
5	Comparison of Dextropropoxyphene and Paracetamol with Paracetamol After Third Molar Dental Extractions. <i>Journal of Pharmacy Practice and Research</i> , <b>2004</b> , 34, 22-25	0.7	
4	Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 1617-26	8.3	64
3	Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. <i>Journal of Chemical Information and Computer Sciences</i> , <b>2003</b> , 43, 2019-24		67
2	In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2003</b> , 30, 836-40	3	18
1	Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. <i>Pharmacogenetics and Genomics</i> , <b>2002</b> , 12, 635-45		71